Meta AnalysisID 6328
rhBNP-芪苈强心胶囊序贯治疗心力衰竭的有效性和安全性：一项Meta分析与GRADE证据质量评价
CRD42023407631
Systematic evaluation of the efficacy and safety of recombinant human brain natriuretic peptide(rhBNP)-QLQX in the sequential treatment of heart failure.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6328
- Evidence Id
- 14886
- Core Evidence Id
- 14886
- Source Meta Analysis Id
- 6312
- Herb2 Meta Analysis Id
- HBMA006312
- Crd Id
- CRD42023407631
- Title
- Efficacy and safety of sequential treatment with rhBNP-Qiliqiangxin capsule in heart failure: A Meta-analysis and quality evaluation of GRADE evidence
- Review Question
- Systematic evaluation of the efficacy and safety of recombinant human brain natriuretic peptide(rhBNP)-QLQX in the sequential treatment of heart failure.
- Study Type Included
- Only RCTs
- Condition Being Studied
- Heart failure(HF) is a serious manifestation and end stage of various cardiovascular diseases. It is a clinical syndrome caused by various kinds of cardiac damage that reduces cardiac output and cannot meet the metabolic needs of body tissues, with dyspnea, weakness and fluid retention as the main clinical manifestations, eventually leading to the decline of heart pumping function, with the characteristics of recurrent attacks and continuous progress.Patients with HF still have a high prevalence and mortality rate. Conventional drug treatment can improve symptoms in the short term but cannot reduce the incidence of rehospitalization, and side effects are inevitable.Qiliqiangxin capsule(QLQX) is widely used as a complementary and alternative treatment for HF. Systematic evaluation of the efficacy and safety of recombinant human brain natriuretic peptide(rhBNP)-QLQX in the sequential treatment of heart failure.
- Participant
- Subjects included in the study met the diagnostic criteria for heart failure in the Chinese Society of Cardiovascular Diseases.Patients whose interventions include Chinese herbal medicines, proprietary Chinese medicines or Chinese medicinal preparations other than Astragalus capsules will be excluded
- Animal
- Human Disease Modelled
- Intervention
- The experimental group and control group were treated with conventional therapy, including low-flow oxygenation, low-salt diet, correction of electrolyte disturbance, cardiac strengthening, diuresis, and anti-infection, antiplatelet, and lipid regulation, with the addition of rhBNP. The experimental group was treated with QLQX on top of the control group.
- Comparator Control
- The control group were treated with conventional therapy, including low-flow oxygenation, low-salt diet, correction of electrolyte disturbance, cardiac strengthening, diuresis, and anti-infection, antiplatelet, and lipid regulation, with the addition of rhBNP.
- Main Outcome
- The total clinical efficiency:according to the New York Heart Function Classification (NYHA) standard, after treatment, the patient's symptoms/signs improved significantly, heart function improved by grade 2 and heart function reached grade I as very effective, symptoms/signs relieved, heart function improved by grade 1 or heart function reached grade I-II as effective, no improvement of heart function or deterioration of heart function as ineffective; total clinical efficiency = (number of very effective + number of effective) / total number × 100%
- Outcome Measure
- Additional Outcome
- BNP; NT-proBNP; cardiac function indexes (LVEF, LVESD, LVEDD); hemodynamic indexes (HR, SBP, DBP, CO, CI); myocardial injury markers (cTnI, CK-MB, hs-CRP); 6MWT; daily living ability score (BI);Safety indicators: incidence of adverse reactions.
- Study Method
- Systematic review
- Keyword
- Drugs, Chinese Herbal; Heart Failure; Humans; Natriuretic Peptide, Brain; qiliqiangxin
- Contact
- Teng Ma [email protected]
- Organisational Affiliation
- Second Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Funding Source
- Tianjin Municipal Health and Health Commission, Tianjin Administration of Traditional Chinese Medicine：Scientific Research ProjectsEvidence-based and SBAR Model for End-Stage Heart Failure Physician-Nurse integrated management program Grant number(s) <span style=font-size: 14px>State the funder, grant or award number and the date of award</span> 2021112
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-03-14
- Registration Date
- 2023-03-24
- Anticipated Start Date
- 2023-02-14
- Anticipated Completion Date
- 2023-04-12
- Title Cn
- rhBNP-芪苈强心胶囊序贯治疗心力衰竭的有效性和安全性：一项Meta分析与GRADE证据质量评价
- Title En
- Efficacy and safety of sequential treatment with rhBNP-Qiliqiangxin capsule in heart failure: A Meta-analysis and quality evaluation of GRADE evidence
- Bilingual Status
- complete